
1. CMAJ. 2017 Nov 27;189(47):E1448-E1458. doi: 10.1503/cmaj.170494.

Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational
postexposure prophylaxis.

Tan DHS(1), Hull MW(2), Yoong D(2), Tremblay C(2), O'Byrne P(2), Thomas R(2),
Kille J(2), Baril JG(2), Cox J(2), Giguere P(2), Harris M(2), Hughes C(2),
MacPherson P(2), O'Donnell S(2), Reimer J(2), Singh A(2), Barrett L(2), Bogoch
I(2), Jollimore J(2), Lambert G(2), Lebouche B(2), Metz G(2), Rogers T(2),
Shafran S(2); Biomedical HIV Prevention Working Group of the CIHR Canadian HIV
Trials Network.

Author information: 
(1)Division of Infectious Diseases (Tan), St. Michael's Hospital, Toronto, Ont.; 
BC Centre for Excellence in HIV/AIDS (Hull, Harris), Vancouver, BC; Department of
Pharmacy (Yoong), St. Michael's Hospital, Toronto, Ont.; Centre de Recherche du
Centre Hospitalier de l'Université de Montréal (Tremblay), Montréal, Que.; School
of Nursing (O'Byrne), University of Ottawa, Ottawa, Ont.; Clinique L'Actuel
(Thomas), Montréal, Que.; Canadian Association of Nurses in HIV/AIDS Care
(Kille), Vancouver, BC; Clinique du Quartier Latin (Baril), Montréal, Que.;
Direction régionale de santé publique (Cox), Centre intégré universitaire de
santé et de services sociaux du Centre-Sud-de-l'Île-de-Montréal, Montréal, Que.; 
Department of Pharmacy (Giguere), The Ottawa Hospital, Ottawa, Ont.; Faculty of
Pharmacy & Pharmaceutical Sciences (Hughes), University of Alberta, Edmonton,
Alta.; Division of Infectious Diseases (MacPherson), The Ottawa Hospital, Ottawa,
Ont.; Department of Emergency Medicine (O'Donnell), St. Paul's Hospital,
Vancouver, BC; Winnipeg Regional Health Authority (Reimer), Winnipeg, Man.;
Division of Infectious Diseases, Department of Medicine (Singh, Shafran),
University of Alberta, Edmonton, Alta.; Dalhousie University (Barrett), Halifax, 
NS; Divisions of Internal Medicine and Infectious Diseases (Bogoch), Toronto
General Hospital, Toronto, Ont.; Health Initiative for Men (Jollimore),
Vancouver, BC; Institut national de santé publique du Québec (Lambert), Montréal,
Que.; Research Institute of the McGill University Health Centre (Lebouche),
Montréal, Que.; CATIE (Canadian AIDS Treatment Information Exchange) (Rogers),
Toronto, Ont. darrell.tan@gmail.com.
(2)Division of Infectious Diseases (Tan), St. Michael's Hospital, Toronto, Ont.; 
BC Centre for Excellence in HIV/AIDS (Hull, Harris), Vancouver, BC; Department of
Pharmacy (Yoong), St. Michael's Hospital, Toronto, Ont.; Centre de Recherche du
Centre Hospitalier de l'Université de Montréal (Tremblay), Montréal, Que.; School
of Nursing (O'Byrne), University of Ottawa, Ottawa, Ont.; Clinique L'Actuel
(Thomas), Montréal, Que.; Canadian Association of Nurses in HIV/AIDS Care
(Kille), Vancouver, BC; Clinique du Quartier Latin (Baril), Montréal, Que.;
Direction régionale de santé publique (Cox), Centre intégré universitaire de
santé et de services sociaux du Centre-Sud-de-l'Île-de-Montréal, Montréal, Que.; 
Department of Pharmacy (Giguere), The Ottawa Hospital, Ottawa, Ont.; Faculty of
Pharmacy & Pharmaceutical Sciences (Hughes), University of Alberta, Edmonton,
Alta.; Division of Infectious Diseases (MacPherson), The Ottawa Hospital, Ottawa,
Ont.; Department of Emergency Medicine (O'Donnell), St. Paul's Hospital,
Vancouver, BC; Winnipeg Regional Health Authority (Reimer), Winnipeg, Man.;
Division of Infectious Diseases, Department of Medicine (Singh, Shafran),
University of Alberta, Edmonton, Alta.; Dalhousie University (Barrett), Halifax, 
NS; Divisions of Internal Medicine and Infectious Diseases (Bogoch), Toronto
General Hospital, Toronto, Ont.; Health Initiative for Men (Jollimore),
Vancouver, BC; Institut national de santé publique du Québec (Lambert), Montréal,
Que.; Research Institute of the McGill University Health Centre (Lebouche),
Montréal, Que.; CATIE (Canadian AIDS Treatment Information Exchange) (Rogers),
Toronto, Ont.

Erratum in
    CMAJ. 2018 Jun 25;190(25):E782.

DOI: 10.1503/cmaj.170494 
PMCID: PMC5703677
PMID: 29180384  [Indexed for MEDLINE]

Conflict of interest statement: Competing interests: Darrell Tan reports grants
from the Canadian Institutes of Health Research and Ontario HIV Treatment
Network, during the conduct of the study, and personal fees from Merck and GSK
and grants and personal fees from Gilead and ViiV Healthcare, outside the
submitted work. Mark Hull reports receiving honoraria for advisory board
representation and speaking engagements regarding HIV and the hepatitis C virus
from BMS, Gilead, Merck and ViiV Healthcare, paid to his institution. Deborah
Yoong reports personal fees from Merck and Gilead Science, outside the submitted 
work. Cécile Tremblay reports grants and personal fees from Gilead, Merck, ViiV
Healthcare, the Canadian Institutes of Health Research and Fonds de recherche
santé Québec, both during the conduct of the study and outside the submitted
work. Réjean Thomas reports personal fees from Gilead, outside the submitted
work. Jean-Guy Baril reports grants from Gilead, Merck and Glaxo, and personal
fees from Gilead, Merck and ViiV Healthcare, outside the submitted work. Joseph
Cox reports grants and personal fees from ViiV Healthcare, and grants from Merck 
and Gilead, outside the submitted work. Pierre Giguere reports grants and
personal fees from Gilead Sciences, ViiV Healthcare and Merck outside the
submitted work. Marianne Harris reports grants and personal fees from Gilead
Sciences Canada and personal fees from Merck Canada and ViiV Healthcare, outside 
the submitted work. Christine Hughes reports grants and personal fees from ViiV
Healthcare, and personal fees from Merck Canada and Gilead Sciences Canada,
outside the submitted work. Stephen Shafran reports grants from AbbVie, Gilead
and Janssen; grants and personal fees from Merck and BMS; and personal fees from 
Pfizer, outside the submitted work. No other competing interests were declared.

